ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
Diffuse Large B-Cell Lymphoma - Experience from a Tertiary Care Hospital in Eastern India.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common and a morphologically, molecularly, and clinically heterogeneous group of non-Hodgkin's lymphoma (NHL) whose outcomes have greatly improved after rituximab-based chemotherapy. The present Indian study is unique as we have analysed the data of DLBCL patients based on cell of origin, clinical features, and outcomes with rituximab-based chemotherapy. In this retrospective observational study from 2016-2023, the medical records of 580 DLBCL patients were analysed. The cell of origin was based on immunohistochemistry using the Hans algorithm. The median age of presentation was 55 years, with the Activated B-cell (ABC) type being the most common. Stage IV disease was observed in 41% of the patients. As per International Prognostic Index (IPI) risk stratification, 38% and 36% of the patients were in the low intermediate (LI) and high intermediate (HI) risk groups, respectively. Extranodal involvement, B symptoms, and bulky disease were seen in 26%, 46%, and 29% of the patients, respectively. R-CHOP chemotherapy was used in 75% of the patients. Complete response was seen in 73% and 43% in the germinal centre B-cell (GCB) type and ABC type, respectively. Other factors associated with lower rates of complete response were female sex, Stage II/IV, IPI-HI/H, Bulky disease, and non-R-CHOP chemotherapy use. The overall two-year PFS rate was 78%, with 87.6% in the GCB and 70.5% in the ABC type, respectively. Two-year overall survival was 81.4% (87.7% for GCB, 73.5% for ABC and 90.1% for others). Clinical trial registration: Nil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.